Simultaneous 18F Choline Positron Emission Tomography/Magnetic Resonance Imaging of the Prostate: Initial Results

PurposeThe purposes of this study were to evaluate the feasibility of simultaneous 18F choline positron emission tomography (PET) and magnetic resonance imaging (MRI) of the prostate and to present the first clinical results of the method. Materials and MethodsFrom March 2012 to October 2012, a total of 15 consecutive patients were examined with simultaneous 18F choline PET/MRI. At the time of the examination, 8 patients had histologically proven prostate cancer, 2 patients had repeated prostate biopsies with negative results, and 5 patients had suspected prostate cancer with an elevated or rising prostate specific antigene level but did not have a prostate biopsy. Sequence protocol comprised T2-weighted high-resolution images and diffusion-weighted images of the prostate in addition to PET imaging. Image quality was assessed by 2 radiologists, and the PET images were evaluated qualitatively and quantitatively. ResultsSimultaneous PET/MRI of the prostate was accomplished successfully in all patients. The method proved to be robust without technical failure, and the image quality was rated to be diagnostic in all examinations except in 1 diffusion-weighted imaging (DWI) data set that was judged to be nondiagnostic because of susceptibility artifacts. High-resolution T2-weighted images allowed exact correlation of elevated focal or diffuse choline uptake to suspicious T2-weighted lesions of the prostate. A high accordance was found between PET and DWI. However, PET-positive lesions were found in 3 patients wherein DWI did not indicate tumor in suspicious T2-weighted lesions. ConclusionsSimultaneous positron emission tomography/magnetic resonance imaging of the prostate has the advantage of combining high-resolution prostate images, functional studies, and metabolic/molecular imaging. The PET component adds diagnostic confidence to the MRI-based parameters in identifying and localizing tumor in the prostate.

[1]  Thomas Hambrock,et al.  Initial Experience With Identifying High-Grade Prostate Cancer Using Diffusion-Weighted MR Imaging (DWI) in Patients With a Gleason Score ⩽3 + 3 = 6 Upon Schematic TRUS-Guided Biopsy: A Radical Prostatectomy Correlated Series , 2012, Investigative radiology.

[2]  B. Krause,et al.  Choline PET and PET/CT in Primary Diagnosis and Staging of Prostate Cancer , 2012, Theranostics.

[3]  G. Bauman,et al.  18F-fluorocholine for prostate cancer imaging: a systematic review of the literature , 2011, Prostate Cancer and Prostatic Diseases.

[4]  I. Sesterhenn,et al.  Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  G. V. von Schulthess,et al.  Fluorocholine PET/CT in patients with prostate cancer: initial experience. , 2005, Radiology.

[6]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[7]  S Mattsson,et al.  Biokinetics of 18F-choline studied in four prostate cancer patients. , 2010, Radiation protection dosimetry.

[8]  M. Schouten,et al.  Predictive value of MRI in the localization, staging, volume estimation, assessment of aggressiveness, and guidance of radiotherapy and biopsies in prostate cancer , 2012, Journal of magnetic resonance imaging : JMRI.

[9]  Baris Turkbey,et al.  Multiparametric MRI and prostate cancer diagnosis and risk stratification , 2012, Current opinion in urology.

[10]  Nassir Navab,et al.  Tissue Classification as a Potential Approach for Attenuation Correction in Whole-Body PET/MRI: Evaluation with PET/CT Data , 2009, Journal of Nuclear Medicine.

[11]  R. Shah,et al.  Introducing Parametric Fusion PET/MRI of Primary Prostate Cancer , 2012, The Journal of Nuclear Medicine.

[12]  L. R. Jensen,et al.  Peripheral Zone Prostate Cancer Localization by Multiparametric Magnetic Resonance at 3 T: Unbiased Cancer Identification by Matching to Histopathology , 2012, Investigative radiology.

[13]  Mario Marengo,et al.  Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  J. Fütterer,et al.  ESUR prostate MR guidelines 2012 , 2012, European Radiology.

[15]  R. Tiling,et al.  Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  P. Waldenberger,et al.  18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. , 2010, Radiology.